

REVIEW ARTICLE

Therapeutic approaches to Alzheimer's disease

Hans-Wolfgang Klafki,¹ Matthias Staufenbiel,² Johannes Kornhuber¹ and Jens Wiltfang^{1,*}¹Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany and²Novartis Institutes for Biomedical Research, Basel, Switzerland

*Correspondence to: Jens Wiltfang, Department of Psychiatry, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
E-mail: jens.wiltfang@psych.imed.uni-erlangen.de

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting ~5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression. The search for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms has been a major focus of research and it is expected that novel medications with disease-modifying properties will emerge from these efforts in the future. In this review, currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.

Keywords: amyloid plaques; neurofibrillary tangles; tau pathology; therapeutic strategies

Abbreviations: A β = amyloid- β peptide; AchE = acetylcholinesterase; APP = amyloid precursor protein; NFTs = neurofibrillary tangles; NMDA = N-methyl-D-aspartate; PHFs = paired helical filaments; PS1 and PS2 = presenilin-1 and -2

Received July 4, 2006. Revised August 25, 2006. Accepted August 31, 2006. Advance Access publication October 3, 2006

Introduction

Alzheimer's disease is the most common cause of progressive dementia in the elderly population. It is a chronic neurodegenerative disorder that leads to progressive disturbances of cognitive functions including memory, judgement, decision-making, orientation to physical surroundings and language (Nussbaum and Ellis, 2003). Characteristic neuropathological findings include selective neuronal and synaptic losses (Morrison and Hof, 1997), extracellular neuritic plaques containing the β -amyloid peptide (Glennier and Wong, 1984; Masters *et al.*, 1985) and neurofibrillary tangles (NFTs) composed of hyperphosphorylated forms of the tau protein (Delacourte and Defossez, 1986; Grundke-Iqbal *et al.*, 1986a, b; Kosik *et al.*, 1986; Goedert *et al.*, 1988, 1992; Wischik *et al.*, 1988; Flament *et al.*, 1989; Lee *et al.*, 1991; Hasegawa *et al.*, 1992; Sergeant *et al.*, 1995). The clinical picture of dementia, as well as the histological findings of amyloid plaques and NFTs, was described as

early as 1906 by the German psychiatrist Alois Alzheimer at a conference in Tübingen (reviewed by Maurer *et al.*, 1997). His findings were published in his famous report 'Über eine eigenartige Erkrankung der Hirnrinde' ['A characteristic disease of the cerebral cortex'] in 1907 (Alzheimer, 1907). In his 1911 publication, Alzheimer reported his second case of dementia and also included drawings of the typical neurofibrillary changes from his first case (Alzheimer, 1911; for reviews on Alzheimer's work and contributions of others in this context, see Bick, 1994; Maurer *et al.*, 1997; Burns *et al.*, 2002). Although discovered already a century ago, plaques and tangles are, till today, still the defining criteria for a definite post-mortem diagnosis.

It has been estimated that ~5% of the population older than 65 years is affected by Alzheimer's disease (Bullock, 2004). The prevalence doubles approximately every 5 years beyond age 65 (Cummings, 2004) and some studies suggest

that nearly half of the people aged 85 years and older suffer from this devastating disorder (Forsyth and Ritzline, 1998).

Due to the demographic development of Western societies, undoubtedly the number of patients and the economic impact of Alzheimer's disease will grow extraordinarily in the future without advances in therapy or prevention.

Current medications that have passed FDA approval for the treatment of Alzheimer's disease include acetylcholinesterase (AChE) inhibitors for mild to moderate cases, and memantine, an NMDA (*N*-methyl-D-aspartate)-receptor antagonist for the treatment of moderate to severe Alzheimer dementia. All of these drugs seem to be able to produce modest symptomatic improvements in some of the patients (for review, see Clark and Karlawish, 2003; Cummings, 2004; Scarpini *et al.*, 2003), none of the available medications, however, appears to be able to cure Alzheimer's dementia or to stop the disease progression.

There is enormous medical need for the development of novel therapeutic strategies that target the underlying pathogenic mechanisms in Alzheimer's disease and that are therefore expected to lead to new medications with strong disease-modifying properties.

Current status: symptomatic strategies

Cholinergic deficit

According to the 'cholinergic hypothesis of Alzheimer's dementia' the destruction of cholinergic neurons in the basal forebrain and the resulting deficit in central cholinergic transmission contribute substantially to the characteristic cognitive and non-cognitive symptoms observed in the patients (Bartus *et al.*, 1982; Cummings and Back, 1998). Reductions in the activities of choline acetyltransferase and AChE in brain tissues from Alzheimer's disease patients were first reported in 1976 and 1977 (Bowen *et al.*, 1976; Davies and Maloney, 1976; Perry *et al.*, 1977). These enzymes are involved in the synthesis and degradation of acetylcholine, and the observed reduction in Alzheimer's disease suggested a selective destruction of cholinergic neurons. The cholinergic hypothesis provided the rational basis for the development of the AChE inhibitors for Alzheimer's disease therapy. Alternative approaches aiming for improved cholinergic neurotransmission, such as the administration of acetylcholine precursors, the stimulation of presynaptic acetylcholine release or muscarinic agonists were not successful due to lack of efficacy or because of severe side effects (Doody *et al.*, 2001). The acetylcholine deficiency hypothesis was primarily supported by post-mortem examinations of brains from patients with advanced dementia (Bartus *et al.*, 1982; Perry, 1986; Whitehouse *et al.*, 1986). The underlying assumption that the cholinergic deficits occur early in the course of the disease has been challenged by more recent studies reporting that the activities of the marker enzymes choline acetyltransferase and AChE were not reduced in individuals with mild Alzheimer's disease

(Davis *et al.*, 1999), and that cholinergic activity may be even up-regulated in early stage of the disease (DeKosky *et al.*, 2002; Frolich, 2002).

Inhibition of brain cholinesterase activity

After its release into the synaptic cleft the neurotransmitter acetylcholine is degraded rapidly by the hydrolytic activity of cholinesterases. In the human brain, the most prominent enzyme involved in acetylcholine hydrolysis is AChE. Recent evidence suggests that additionally, butyrylcholinesterase (BChE) can also hydrolyse acetylcholine in the brain and may play a role in cholinergic transmission (Mesulam *et al.*, 2002*a, b*).

Inhibition of these enzymes leads to an increase in the acetylcholine concentration in the synaptic cleft and is thus expected to enhance cholinergic transmission and ameliorate cholinergic deficit. Three different cholinesterase inhibitors, namely galantamine, donepezil and rivastigmine are commonly used for the treatment of mild to moderate Alzheimer's disease. Donepezil and galantamine are selective inhibitors of AChE, while rivastigmine also inhibits BChE, which accounts for ~10% of the cholinesterase activity in normal human brain and appears to be predominantly associated with glia (reviewed in Scarpini *et al.*, 2003).

Several randomized, double-blind, placebo-controlled studies reported positive effects of the cholinesterase inhibitors on cognitive and functional symptoms, as well as on behavioural abnormalities in Alzheimer's dementia (Rogers *et al.*, 1998; Corey-Bloom, 1998; Rosler *et al.*, 1999; Tariot *et al.*, 2000; Winblad *et al.*, 2001). Systematic reviews of the available randomized, double-blind, placebo-controlled studies by the Cochrane Collaboration support the use of the three cholinesterase inhibitors rivastigmine (Birks *et al.*, 2000), donepezil (Birks and Harvey, 2003) and galantamine (Loy and Schneider, 2004) for treatment of mild to moderate Alzheimer's disease. The treatment effects observed at 6 months were moderate and of similar size for the three substances (reviewed in Scarpini *et al.*, 2003). In line with the Cochrane reviews, clinical benefits from cholinesterase inhibitors were also reported in two other meta-analyses published in 2004 (Whitehead *et al.*, 2004; Ritchie *et al.*, 2004). In a recent systematic review, however, the scientific basis for the recommendations of cholinesterase inhibitors for treatment of Alzheimer's disease has been questioned (Kaduszkiewicz *et al.*, 2005). Further long-term studies including the direct comparisons of the three cholinesterase inhibitors would be desirable.

Glutamate-mediated neurotoxicity

Glutamate excitotoxicity mediated through excessive activation of NMDA receptors is believed to play a role in the neuronal death observed in Alzheimer's disease and other neurodegenerative conditions (reviewed in Bleich *et al.*, 2003; Hynd *et al.*, 2004).

Glutamate represents the main excitatory neurotransmitter in the central nervous system and a physiological level of glutamate-receptor activity is essential for normal brain function (Kornhuber and Weller, 1997). Glutamate receptors can be broadly divided into metabotropic glutamate receptors, which are coupled to G-proteins, and ionotropic receptors, which are ligand gated ion channels. On the basis of their sensitivity to synthetic agonists, the latter are classified into the NMDA, α -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) and kainate receptors (Javitt, 2004).

In Alzheimer's disease, excessive activation of NMDA receptors is believed to cause increases in intracellular Ca^{2+} which then triggers downstream events that ultimately lead to neurodegeneration (for review, see Hynd *et al.*, 2004). Consequently, NMDA-receptor antagonists may have a therapeutic potential for protecting neurons from glutamate-mediated neurotoxicity.

Potent NMDA-receptor antagonists like MK-801 or phencyclidine (PCP) were reported to produce psychotomimetic side effects (Kornhuber and Weller, 1997), presumably due to interference with the physiological functions of NMDA glutamate receptors. Memantine is a non-competitive NMDA-receptor antagonist with moderate affinity (Kornhuber *et al.*, 1989) that appears to be able to protect neurons while leaving physiological NMDA-receptor activation unaffected (reviewed in Sonkusare *et al.*, 2005). Memantine interacts with the NMDA receptor at therapeutic concentrations (Kornhuber and Quack, 1995).

Memantine was approved in 2002 in Europe for the treatment of 'moderately severe to severe Alzheimer's disease' and in 2003 in the United States for the treatment of moderate to severe cases of Alzheimer's disease (Sonkusare *et al.*, 2005). A recent systematic review of double-blind, parallel group, placebo-controlled randomized trials of memantine in people with dementia published by the Cochrane Collaboration suggested a beneficial effect of memantine on cognitive function and functional decline in patients with moderate to severe Alzheimer's disease, and on cognitive function in vascular dementia. The drug was reported to be well-tolerated (Areosa Sastre *et al.*, 2005).

Combination therapy

The positive clinical results of memantine monotherapy and the observation that memantine does not interact *in vitro* with the AChE inhibitors donepezil, galantamine or tetrahydroaminoacridine (Wenk *et al.*, 2000) suggested that the clinical combination of memantine with cholinesterase inhibitors might represent a particularly valuable approach. A randomized, double-blind, placebo-controlled clinical trial of patients with moderate to severe Alzheimer's dementia who had already been adjusted to donepezil was published in January 2004. After 24 weeks, a statistically significant benefit of the combination therapy as compared with the monotherapy was observed with regard to measures of

cognitive function, activities of daily living, behaviour and clinical global status (Tariot *et al.*, 2004).

Mechanism-based therapeutic approaches targeting β -amyloid and tau pathologies

The characteristic neuropathological hallmarks of Alzheimer's disease include neuritic plaques and NFTs (Alzheimer, 1907, 1911). Neuritic plaques are extracellular lesions composed of a central core of aggregated amyloid- β peptide ($\text{A}\beta$) surrounded by dystrophic neurites, activated microglia and reactive astrocytes (Selkoe, 1991). In 1984, Glenner and Wong first reported on the purification and partial amino acid sequence determination of the β -amyloid peptide from cerebrovascular amyloid associated with Alzheimer's disease (Glenner and Wong, 1984). Shortly after, the 4 kDa amyloid protein components purified from the plaque cores from Alzheimer's disease and Down syndrome brains were found to be essentially identical, indicating a common origin (Masters *et al.*, 1985).

NFTs are intracellular bundles of paired helical filaments (PHFs; Kidd, 1963; Terry, 1963) and straight filaments (Yagishita *et al.*, 1981). They are composed of tau protein (Delacourte and Defossez, 1986; Grundke-Iqbal *et al.*, 1986a; Kosik *et al.*, 1986; Goedert *et al.*, 1988; Wischik *et al.*, 1988) in an abnormally hyperphosphorylated form (Grundke-Iqbal *et al.*, 1986b; Flament *et al.*, 1989; Lee *et al.*, 1991; Goedert *et al.*, 1992; Hasegawa *et al.*, 1992; Sergeant *et al.*, 1995). It appears that these two proteinacious lesions are at the root of the pathogenesis of Alzheimer's disease, and consequently it is believed that targeting the underlying mechanisms leading to plaques and tangles will ultimately generate novel therapeutics with disease-modifying properties.

Therapeutic strategies targeting β -amyloid

The amyloid cascade hypothesis

The dominating hypothesis to explain the mechanisms leading to Alzheimer's disease is the amyloid cascade hypothesis, which states that the $\text{A}\beta$, a fragment of the amyloid precursor protein (APP), plays a central role in the pathogenesis. $\text{A}\beta$ is produced proteolytically from APP by the so called β - and γ -secretases. It is believed that accumulation of β -amyloid (in particular of the $\text{A}\beta_{42}$ peptide) in the brain initiates a cascade of events that ultimately leads to neuronal dysfunction, neurodegeneration and dementia (Fig. 1; for a review, see Hardy and Selkoe, 2002).

The strongest argument supporting a causal role of β -amyloid in Alzheimer's disease comes from the identification of mutations in the APP gene (Chartier-Harlin *et al.*, 1991; Goate *et al.*, 1991; Murrell *et al.*, 1991) and in the genes for presenilin-1 and -2 (PS1 and PS2; Levy-Lahad *et al.*, 1995; Sherrington *et al.*, 1995) that are responsible for early-onset forms of familial Alzheimer's disease (FAD). By July 2006,




Fig. 1 Amyloid cascade hypothesis and selected strategies for therapeutic intervention. The figure summarizes the presumed sequence of pathological processes that leads to neurodegeneration in AD according to the amyloid cascade hypothesis (Hardy and Selkoe, 2002), and indicates selected potential approaches for therapeutic intervention. A β 42 is believed to initiate this series of pathogenic events. Modified from: D. Selkoe, 'The amyloid hypothesis'. Alzheimer Research Forum. Available at <http://www.alzforum.org/res/adh/cur/knowtheamyloidcascade.asp>. Accessed in August 2006.

25 pathogenic mutations in *APP*, 155 in *PS1* and 10 in *PS2* were listed on the Alzheimer Disease & Frontotemporal Dementia Mutation Database (Cruts and Rademakers, 2006; <http://www.molgen.ua.ac.be/ADMutations/>). Another online database listing FAD mutations is available at <http://www.alzforum.org/res/com/mut/default.asp>. FAD mutations in *PS1* and *PS2*, as well as mutations in the *APP* gene close to the γ -secretase cleavage site, modify the proteolytic generation of A β peptides in such a way that the relative proportion of the highly amyloidogenic A β 42 form is increased (Suzuki *et al.*, 1994; Tamaoka *et al.*, 1994; Borchelt *et al.*, 1996; Duff *et al.*, 1996; Citron *et al.*, 1997). The so-called 'Swedish' APP double mutation (KM670/671NL)

leads to a rise in overall A β generation due to an increased cleavage by β -secretase (Citron *et al.*, 1992; for reviews, see Hardy and Selkoe, 2002; St George Hyslop and Petit, 2004). A β peptides represent the principal protein component of the neuritic plaques characteristic for Alzheimer's disease and it was shown that aggregated forms of synthetic A β peptides can cause damage to cultured neuronal cells (Pike *et al.*, 1993; Lorenzo and Yankner, 1994). More recent findings suggest that rather than highly aggregated A β species, soluble oligomeric prefibrillar forms of A β [so called A β -derived diffusible ligands (ADDLs) or protofibrils] may represent the neurotoxic entity and cause synaptic dysfunction (Lambert *et al.*, 1998; Hartley *et al.*, 1999).

Transgenic animal models may help to better understand the role of amyloid and tau in the aetiology of Alzheimer's disease and they may also serve for testing novel drug candidate compounds.

Transgenic mice that show robust amyloid plaque pathology were first reported by Games and colleagues in 1995 (Games *et al.*, 1995). These mice expressed high levels of the V717F FAD-mutant form of human APP and developed extracellular amyloid plaques, astrogliosis and neuritic dystrophy. In 1996, transgenic 'Tg2576' mice over-expressing the Swedish APP double mutation were shown to develop Congo red positive amyloid plaques and age-dependent correlative memory deficits (Hsiao *et al.*, 1996). Sturchler-Pierrat and colleagues (1997) generated the APP23 line expressing Swedish mutant APP under control of the Thy-1 promoter. These mice developed typical plaques and showed signs of inflammatory reactions as well as cerebrovascular amyloid deposits (Sturchler-Pierrat *et al.*, 1997; Calhoun *et al.*, 1999). At age 14–18 months, a selective reduction of neurons in the hippocampal area CA1 was observed (Calhoun *et al.*, 1998). (For a recent review on additional mouse lines that have been generated since then, see McGowan *et al.*, 2006.)

According to the amyloid cascade hypothesis novel therapeutic strategies that lower A β levels or prevent the formation of the presumed neurotoxic oligomeric A β species are predicted to stop or slow down the progression of neurodegeneration and dementia in Alzheimer's disease.

Modulation of A β production

A β peptides are proteolytic fragments of the APP, a large integral membrane protein that is composed of a signal sequence, a large extra-membranous region, a single transmembrane domain and a small cytosolic C-terminal tail (Kang *et al.*, 1987). Post-translational modifications of APP include phosphorylation, tyrosine-sulphation and N- and O-linked glycosylations (Oltersdorf *et al.*, 1990; Weidemann *et al.*, 1989). A β is generated from APP by sequential cleavages by two proteases termed β - and γ -secretase. APP cleavage by the so-called α -secretase, which was the first proteolytic cleavage to be identified, precludes A β generation since the α -secretase cleavage site is located within the A β sequence (Esch *et al.*, 1990; Sisodia *et al.*, 1990). A β is not the result of abnormal or pathological APP processing, as was originally believed, but is secreted constitutively by normal cells in culture (Haass *et al.*, 1992; Shoji *et al.*, 1992) and can be detected in plasma and CSF of healthy humans (Seubert *et al.*, 1992). The observation that γ -secretase activity was prevented in neuronal cells derived from PS1 deficient mouse embryos indicated that PS was tightly linked to the intramembrane cleavage of APP (De Strooper *et al.*, 1998). Two conserved aspartate residues in PS1 located in transmembrane regions were shown to be essential for γ -secretase activity (Wolfe *et al.*, 1999), and subsequent studies revealed that

γ -secretase is a protein complex composed of PS, nicastrin, PEN2 and APH-1. It appears that PS1 provides the active core of the secretase complex and that the enzymatic mechanism is that of an aspartate protease (reviewed in De Strooper, 2003).

Beta-secretase was discovered and cloned in 1999 (Hussain *et al.*, 1999; Sinha *et al.*, 1999; Vassar *et al.*, 1999; Yan *et al.*, 1999) and has been a major focus of drug discovery efforts since then. BACE1 knock-out mice were reported to produce only very small amounts of A β confirming that BACE1 represents the primary β -secretase *in vivo*. Furthermore, the absence of severe phenotypes in the knockout mice (Luo *et al.*, 2001; Roberds *et al.*, 2001), suggests that targeting β -secretase may be a particularly promising therapeutic approach, even though the identification of specific small molecule inhibitors suitable for drug development appears to be difficult (Citron, 2004).

Several pharmaceutical companies have actively searched for small molecule compounds that can reduce A β production by affecting one of these targets.

A γ -secretase inhibiting compound (LY450139) by Eli Lilly was recently tested in a 6-week Phase II trial. The compound was reported to reduce A β levels in plasma but not in CSF at concentrations that did not produce significant side effects (Siemers *et al.*, 2005).

A major concern regarding the therapeutic usefulness of γ -secretase inhibition and potential side effects comes from the identification of several γ -secretase substrates other than APP, including Notch 1 and others (for review, see De Strooper, 2003).

The finding that certain non-steroidal anti-inflammatory drugs (NSAIDs) can preferentially reduce the generation of the highly amyloidogenic A β 42 species without affecting Notch cleavage (Weggen *et al.*, 2001), indicates the existence of a γ -secretase modulating mechanism as a potential drug target that may allow for lowering A β 42 levels without inducing potential side effects related to complete inhibition of γ -secretase. It is reasonable to assume that currently more potent and specific A β 42 lowering compounds are being actively searched for.

Cleavage of APP by non-amyloidogenic α -secretase can be stimulated by muscarinic acetylcholine-receptor agonists, and this was shown to also reduce A β generation in cell culture (Hung *et al.*, 1993; Wolf *et al.*, 1995). M1 muscarinic acetylcholine-receptor agonists were therefore suggested to be potentially useful not only for symptomatic treatment of Alzheimer's disease but to a limited extent also for causal therapy (Fisher, 2000).

The M1 agonist AF267B (Fisher, 2000) was recently tested in triple-transgenic mice expressing mutant forms of presenilin 1, APP and tau (Oddo *et al.*, 2003; Billings *et al.*, 2005). A 10-week treatment of the mice, with daily intraperitoneal injections of the compound, was reported to ameliorate cognitive deficit in the mice and to reduce both, amyloid and tau pathologies (Caccamo *et al.*, 2006).

Inhibition of A β -aggregation

Preventing the formation of the presumed toxic oligomeric aggregates of A β by small molecules represents another promising approach for the development of novel and causal therapeutics for treating Alzheimer's disease.

Neurochem Inc., a Canadian company, has completed a Phase II clinical trial of their glycosaminoglycan mimetic Alzhemed that has been designed to bind to A β peptides and thereby inhibits formation of A β aggregates. A phase III trial is planned (reviewed in Citron, 2004).

Metal ions like Cu²⁺ and Zn²⁺ may be involved in the mediation of A β aggregation and toxicity (Atwood *et al.*, 1998). A significant decrease in brain A β deposition in APP-transgenic mice was observed after 9 weeks treatment with clioquinol, an antibiotic and Cu/Zn chelator that crosses the blood–brain barrier (Cherny *et al.*, 2001). Recently Prana Biotechnology cancelled an upcoming Phase II/III clinical trial of clioquinol (PBT-1) because of toxic impurities believed to occur during the manufacture (Boggs, 2005; Prana Biotechnology, 2005).

A β immunotherapy

In a landmark paper in 1999 Dale Schenk and co-workers described that immunization with A β attenuates the Alzheimer's disease-like pathology in a transgenic mouse model of Alzheimer's disease (Schenk *et al.*, 1999). Using peripheral antibody administration the same group provided direct evidence that A β antibodies are sufficient to reduce the amyloid deposition (Bard *et al.*, 2000). These fundamental observations have meanwhile been confirmed in different transgenic Alzheimer's disease models as well as in aged non-human primates, which develop some brain amyloid in particular cerebral amyloid angiopathy (CAA; Lemere *et al.*, 2004). Furthermore, A β immunization was shown to also reduce various aspects of the amyloid-associated pathology including neuritic dystrophy and synaptic degeneration as well as early tau accumulation (Lombardo *et al.*, 2003; Oddo *et al.*, 2004; Brendza *et al.*, 2005; Buttini *et al.*, 2005).

These histopathological normalizations also result in functional improvements. Active and passive immunization against A β can reduce the learning deficits of APP-transgenic mice (Janus *et al.*, 2000; Morgan *et al.*, 2000). An amelioration of memory deficits can already be found after short term and even a single passive immunization in the absence of an amyloid reduction (Dodart *et al.*, 2002; Kotilinek *et al.*, 2002). This lack of correlation with amyloid deposits probably reflects the fact that some behavioural deficits seem to be induced by amyloid deposits while others may be more acutely caused by soluble A β species (oligomers). In accordance A β immunization has been demonstrated to neutralize infused A β oligomers and to improve synaptic plasticity impaired by these oligomers (Hartman *et al.*, 2005; Klyubin *et al.*, 2005).

Three different, though not mutually exclusive, mechanisms have been proposed to explain the amyloid lowering

effect of A β immunization. Following the detection of antibodies bound to brain amyloid deposits it has been postulated that they trigger Fc-receptor-mediated phagocytosis (Schenk *et al.*, 1999; Bard *et al.*, 2000). Compatibly, microglia activation, increased Fc γ -receptor expression and a superior efficacy of IgG2a antibodies showing highest Fc γ -receptor affinity have been observed (Schenk *et al.*, 1999; Bacskai *et al.*, 2001; Bard *et al.*, 2003; Wilcock *et al.*, 2003; Bussiere *et al.*, 2004; Wilcock *et al.*, 2004b). In addition, *in vivo* efficacy of A β antibodies correlated with their ability to induce phagocytosis in an *in vitro* system (Bard *et al.*, 2000). As an alternative mechanism, the antibodies might act as chaperones and disrupt A β aggregates or prevent aggregation (Solomon *et al.*, 1997). Supporting this hypothesis, antibodies can block and even reverse A β aggregation and toxicity *in vitro* (Solomon *et al.*, 1997; Frenkel *et al.*, 2000; McLaurin *et al.*, 2002; Du *et al.*, 2003). *In vivo* Fc-receptor independent clearance of amyloid deposits has been observed with F(ab')₂ fragments and in a Fc γ -receptor knock-out background (Bacskai *et al.*, 2002; Das *et al.*, 2003; Wilcock *et al.*, 2004a). While evidence for both hypotheses seems contradictory, a possible explanation comes from a study describing a rapid microglia-independent clearance of diffuse amyloid followed by a microglia-dependent elimination of compact plaques (Wilcock *et al.*, 2003). Finally, circulating antibodies were postulated to sequester A β , shift the equilibrium towards the periphery and thereby reduce brain A β deposition (DeMattos *et al.*, 2001). Consistent with this peripheral sink hypothesis an elevation of blood A β after immunization has been found (DeMattos *et al.*, 2001; Pfeifer *et al.*, 2002; Lemere *et al.*, 2003; Gandy *et al.*, 2004; Lemere *et al.*, 2004; Wilcock *et al.*, 2004b) which reflected the brain amyloid burden (DeMattos *et al.*, 2002). Yet, this could also be explained by a simple stabilization of blood A β due to antibody binding. At present it is not possible to exclude any of the three hypothetical action mechanisms as they may act in concert and depend on the particular experimental paradigm (e.g. level of A β generation, isoform ratios and amyloid type, as well as, stage of amyloid formation or route of administration). More studies, which better consider these parameters, will be needed to determine their relative contribution to the overall effects.

The first clinical trials of A β immunotherapy, which used aggregated A β 1–42 as antigen, had to be stopped in Phase II due to aseptic meningoencephalitis in 6% of the treated patients (Orgogozo *et al.*, 2003; Bayer *et al.*, 2005; Gilman *et al.*, 2005). Autopsy studies of two affected patients demonstrated a T-cell-mediated autoimmune response (Ferrer *et al.*, 2004; Nicoll *et al.*, 2003) presumably directed against A β . The use of full-length A β containing T-cell epitopes (Monsonogo *et al.*, 2003) with a strong T-cell adjuvant (QS21; Cribbs *et al.*, 2003) and the supplementation of the vaccine by polysorbate-80 (Tween-80) during the Phase II trial (Gilman *et al.*, 2005) may have contributed to the adverse response. Evidence for efficacy of A β

immunotherapy was obtained in the first three autopsies, which showed extensive neo-cortical areas devoid of amyloid plaques and associated dystrophic neurites and astrocytes, while amyloid angiopathy and the NFTs were not reduced (Nicoll *et al.*, 2003; Ferrer *et al.*, 2004; Masliah *et al.*, 2005). Clinically, antibody responders significantly improved over 1 year in some memory tests, while others did not change significantly (Gilman *et al.*, 2005). In a small subset tested for CSF tau a significant decrease was found indicative of a reduced degeneration. MRI detected greater brain volume decreases and ventricular enlargements in antibody responders, which is not understood but the amyloid removal may directly or indirectly be responsible for this effect (Fox *et al.*, 2005). Considering the limitations of the study, as well as the positive trends in several efficacy measures, additional testing of A β immunotherapy seems warranted if the safety issues can be addressed.

Extensive studies of active A β immunization in mice and other species had not predicted autoimmune disease although meningoencephalitis (Lee *et al.*, 2005a) as well as an elevation in cerebral haemorrhages (Pfeifer *et al.*, 2002; Wilcock *et al.*, 2004c; Racke *et al.*, 2005) has meanwhile been described after passive immunization. While the significance of these findings with respect to the adverse events in the active immunization study in humans remains open, the findings need to be considered in the development of alternative approaches. These mainly aim to avoid the unwanted T-cell response. For active immunization alternative adjuvants (Cribbs *et al.*, 2003; Maier *et al.*, 2005), use of the mucosal immune system (Weiner *et al.*, 2000; Leverone *et al.*, 2003) or of A β fragments (Li *et al.*, 2004c; Agadjanyan *et al.*, 2005; Solomon, 2005; Zurbriggen *et al.*, 2005) are exploited. The A β peptides used span the B-cell epitopes in the N-terminal part and are linked to carrier proteins including viral structures or other independent T-cell epitopes, which should not induce an A β -specific T-cell response. Passive A β immunotherapy with monoclonal antibodies is being evaluated, as well as DNA vaccines expressing A β and fragments thereof. If these second generation approaches show the expected safety profile A β immunotherapy holds promise as a disease-modifying Alzheimer's disease therapy.

Therapeutic strategies targeting tau hyperphosphorylation and neurofibrillary degeneration

Neurofibrillary lesions made up from aggregated hyperphosphorylated forms of the microtubule-associated protein tau represent a second defining neuropathological feature of Alzheimer's disease. The pathological hyperphosphorylation of tau, which can be visualized by immunochemical methods, is an early event in the development of Alzheimer's disease-related neurofibrillary changes (Braak and Braak, 1995). Phosphorylation of tau

regulates its ability to promote microtubule assembly (Lindwall and Cole, 1984) and abnormal hyperphosphorylation interferes with its normal biological function (Gustke *et al.*, 1992; Bramblett *et al.*, 1993; Alonso *et al.*, 1994) by decreasing tau's ability to bind to, and to stabilize, microtubules. This loss of function can be restored *in vitro* by dephosphorylation of pathological tau protein with phosphatases (Iqbal *et al.*, 1994). Under pathological conditions, an imbalance of kinase and phosphatase activities may lead to aberrant hyperphosphorylation of tau resulting in its detachment from microtubules, breakdown of the microtubule network, disturbance of axonal transport and ultimately neurodegeneration (Mandelkow and Mandelkow, 1998; Fig. 2). Additionally, certain pathological forms of tau may also have direct neurotoxic properties ('gain of toxic function'; Shahani and Brandt, 2002). The identification of mutations in the tau gene that are responsible for familial frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) indicated that malfunction or dysregulation of tau alone can be sufficient to induce neurodegeneration (Hutton *et al.*, 1998; Spillantini *et al.*, 1998). Until now, 40 different pathogenic tau mutations have been reported that cause frontotemporal dementia (Cruts and Rademakers, 2006; Alzheimer Disease and Frontotemporal Dementia Mutation Database; available at <http://www.molgen.ua.ac.be/ADMutations/>). The neuropathology in these cases is characterized by neuronal loss and the presence of neuronal or neuronal and glial aggregates of hyperphosphorylated tau protein (Lee *et al.*, 2001; Dermaut *et al.*, 2005). The molecular details of tau-related neurodegeneration and the identity of the presumed neurotoxic species are not well understood, yet. Recent findings in transgenic mice expressing non-mutant human tau isoforms, suggest that neuronal death may not be directly linked to the formation of the highly aggregated NFTs (Andorfer *et al.*, 2005). In line with these observations, Santacruz and co-workers reported functional improvements but ongoing NFT formation in transgenic mice after suppression of mutant human tau expression (Santacruz *et al.*, 2005).

The inhibition of tau-related neurofibrillary degeneration represents a highly promising approach in search for novel therapies for Alzheimer's disease and related tauopathies. This may be achieved by targeting one or more tau kinase(s), by increasing the activity of protein phosphatase (PP)-2A or by inhibition of the presumed toxic properties of pathological tau proteins.

Inhibition of tau kinases

More than 30 phosphorylation sites on tau protein have been described and numerous proline directed and non-proline directed kinases were shown to be able to phosphorylate tau protein *in vitro*. These include glycogen synthase kinase 3- β (GSK3- β), cdc2-like kinase (cdk5), extracellular signal-regulating kinase-2 (ERK2), microtubule-affinity-regulating




Fig. 2 A hypothetical sequence of events leading to neurofibrillary degeneration in Alzheimer's disease: under pathological conditions (possibly triggered by oligomeric A β) an imbalance of phosphatase and kinase activities results in abnormal hyperphosphorylation of tau protein. Release of hyperphosphorylated tau protein destabilizes microtubules which affects axonal transport and leads to synaptic dysfunction and degeneration. Unbound tau protein can aggregate and form NFTs. Hyperphosphorylated and/or aggregated tau species may have direct neurotoxic effects ('toxic gain of function').

kinase (MARK), protein kinase A (PKA), members of the stress-activated protein kinase (SAPK) family, Ca²⁺/calmodulin-dependent kinase II and casein kinases I and II (for reviews see Johnson and Hartigan, 1998; Buee *et al.*, 2000).

While it is clear that aberrant phosphorylation of tau protein is a key feature of neurofibrillary degeneration, the exact role of particular phosphorylation sites on tau and the identity of the relevant protein kinases that contribute to their phosphorylation under pathological conditions remain elusive.

Of the many potential tau kinases, GSK3 β and cdk5/p25 have received particular attention. Cruz *et al.* (2003), reported that inducible over-expression of the cdk5 activator p25 in the postnatal forebrain of transgenic mice resulted in tau hyperphosphorylation and aggregation as well as in neuronal loss, providing strong evidence that aberrant kinase activity can lead to neurodegeneration. When transgenic mice over-expressing p25 were crossed with mice transgenic for human tau carrying the P301L FTDP-17 mutation, an increase in tau hyperphosphorylation and aggregation relative to P301L tau single transgenic mice was observed. Interestingly, in these double transgenic mice insoluble tau was associated with activated GSK3, suggesting that although p25/ckd5 provided the initial trigger, at least one additional kinase (GSK3) appeared to be involved (Noble *et al.*, 2003).

While sarcosyl-insoluble hyperphosphorylated tau was increased in these double transgenic mice, this was apparently not associated with significantly accelerated dystonia as compared with the P301L tau single transgenic mice.

Neuronal inducible over-expression of GSK3- β in hippocampus and cortex of transgenic mice was shown to increase tau phosphorylation at the PHF1 epitope, to induce somatodendritic localization of tau and to lead to neurodegeneration (Lucas *et al.*, 2001). While these observations clearly support GSK3- β as a tau kinase *in vivo*, its role in the tau-related pathology remains somehow controversial: in double transgenic mice expressing wild-type human tau and a constitutively active form of GSK3- β , a 2-fold increase in GSK3- β kinase activity appeared to reduce the neuropathology and motor impairments that were observed in single tau transgenic mice, (Spittaels *et al.*, 2000).

Another candidate kinase that has been implicated in abnormal hyperphosphorylation of tau is the MAP kinase ERK2, which can phosphorylate tau *in vitro* at many of the Ser/Thr-Pro motifs and to high stoichiometry (Roder and Ingram, 1991; Drewes *et al.*, 1992). Importantly, ERK2 and several members of the SAPK family but not GSK3 and cdk5 (neuronal cdc2-like kinase) were shown to be able to phosphorylate tau at Ser422, which is one of very few phosphorylation sites that appear to be specific for

disease (Hasegawa *et al.*, 1996; Goedert *et al.*, 1997). Activated forms of ERK1/2 and the upstream activating kinases MEK1/2 were shown to co-distribute with the progressive neurofibrillary changes in Alzheimer's disease (Pei *et al.*, 2002; Perry *et al.*, 1999).

In cell-culture experiments, however, stimulation of MAP kinase by v-raf transformation did not induce tau hyperphosphorylation (Latimer *et al.*, 1995), nor did inhibitors of the classical MEK–ERK activation pathway prevent tau hyperphosphorylation in cellular models involving okadaic acid (Ho *et al.*, 1997) or arsenite (Giasson *et al.*, 2002).

Several animal models have been developed, that reproduce characteristic features of tau-related neurofibrillary degeneration and that may serve for testing novel kinase inhibitors *in vivo* to evaluate their therapeutic potential and to assess the role of particular kinases in tau filament formation and neurodegeneration. These models include for example transgenic mice expressing FTDP-17 mutant forms of human tau (Lewis *et al.*, 2000; Gotz *et al.*, 2001) as well as novel triple-transgenic mice developing both, tau and amyloid pathologies (Oddo *et al.*, 2003).

Recently, Noble and co-workers reported that chronic inhibition of GSK3 for 30 days *in vivo* by lithium reduced tau hyperphosphorylation at several sites and decreased the levels of aggregated insoluble tau in JNPL3 transgenic mice over-expressing mutant human tau (Noble *et al.*, 2005). Strong *in vivo* evidence that inhibition of pathological tau hyperphosphorylation can also have a functional impact and therefore represents a particularly promising therapeutic strategy comes from a very recent study. Le Corre and co-workers treated JNPL3 mice transgenic for P301L mutant tau for 9 weeks with a novel orally available and blood–brain-barrier-penetrating synthetic kinase inhibitor. The compound was selected from a series of synthetic indolocarbazoles with limited kinase selectivity but capable of preventing tau hyperphosphorylation in cell and brain slice culture models. A significant delay in the onset of the typical motor deficits in these mice was observed in the treated group as compared to the controls, and this was accompanied by a reduction in abnormal tau hyperphosphorylation (Le Corre *et al.*, 2006). Taken together, these observations strongly support the use of inhibitors of aberrant phosphorylation of tau as an approach to developing a disease-modifying treatment for Alzheimer's disease and other tau-related neurodegenerative diseases.

Prolyl-isomerase Pin1

In 1999, Lu *et al.* discovered that the peptidyl prolyl *cis/trans* isomerase Pin1 bound to tau protein phosphorylated at Thr231 and co-purified with PHFs from Alzheimer's disease brain. *In vitro*, Pin1 was shown to restore the ability of phosphorylated tau to promote microtubule assembly (Lu *et al.*, 1999). Additionally, Pin1 can facilitate dephosphorylation of tau by phosphatase PP2A (Zhou *et al.*, 2000).

Pin1 knockout mice were reported to develop tau hyperphosphorylation, sarcosyl-insoluble filamentous tau aggregates and neuronal degeneration in an age-related fashion (Liou *et al.*, 2003). These observations suggest that Pin 1 may have protective functions against age-related neurodegeneration (Lu, 2004). Ramakrishnan *et al.* (2003) reported the detection of Pin1 granules in early stages of Alzheimer's disease, FTDP-17 (P301L) and Pick's disease and discussed several different possible scenarios concerning Pin1's role in tauopathies. One of these suggested that Pin1 may be involved in the pathogenesis and may promote the development of neurofibrillary pathology. Understanding the exact role of Pin1 in disease will be a prerequisite to evaluate Pin1 as a potential novel therapeutic target.

Activation of phosphatases

The phosphorylation state of any phosphoprotein results from the activities of both, kinases and phosphatases. It has been suggested, that in Alzheimer's disease, an imbalance of kinase and phosphatase activities may lead to abnormal hyperphosphorylation of tau protein (Mandelkow and Mandelkow, 1998). Reduced activities of tau-phosphatases have been reported in Alzheimer's disease brain as compared to controls (Gong *et al.*, 1995). Protein phosphatases PP2A, PP2B and, to a lesser extent PP1, can dephosphorylate tau protein *in vitro* (reviewed in Lau *et al.*, 2002). Additionally, PP2A was also shown to be involved in the regulation of tau phosphorylation *in vivo* (Gong *et al.*, 2000). Expression of a dominant negative form of PP2A in transgenic mice under control of a neuron-specific promoter resulted in a 34% reduced activity of PP2A, and induced tau hyperphosphorylation at Ser202/Thr205 and Ser422 (Kins *et al.*, 2001).

Thus, it has been suggested that in addition to kinase inhibition, restoration or up-regulation of tau phosphatase activities (e.g. PP2A) may represent another potential approach to inhibition of abnormal tau hyperphosphorylation (Iqbal and Grundke-Iqbal, 2004).

Memantine, an NMDA-receptor antagonist approved for the treatment of moderate to severe Alzheimer's disease was recently reported to inhibit okadaic acid-induced abnormal tau hyperphosphorylation and the associated neurodegeneration in rat hippocampal slices. Interestingly, it was suggested that memantine exerted this effect by restoration of PP2A activity through 'PP2A signalling' (Li *et al.*, 2004b).

Inhibition of tau aggregation

Filamentous tau lesions in the affected brain regions represent the defining neuropathological features of tauopathies (for reviews, see Tolnay and Probst, 1999; Lee *et al.*, 2001). In Alzheimer's disease, the intraneuronal NFTs contain PHFs as the major and straight filaments as a minor component, both of which are composed of hyperphosphorylated tau proteins (*see above*). The neurofibrillary lesions in Alzheimer's disease develop in a predictable

spatiotemporal sequence, and the six stages of disease progression have been defined by Braak and Braak (1991, 1995). NFTs were shown to correlate with neuronal loss (Fukutani *et al.*, 1995; Gomez-Isla *et al.*, 1997) and with severity of dementia (Arriagada *et al.*, 1992; Wilcock and Esiri, 1982). The hypothesis that tau aggregation and NFT formation are directly linked to neurodegeneration is supported by recent observations from cultured neuroblastoma cells inducibly over-expressing tau fragments. Only those mutant tau fragments that formed aggregates but not soluble forms were found to be cytotoxic (Khlistunova *et al.*, 2006). Thus, substances that can inhibit tau aggregation might have the potential to ultimately protect neurons from neurofibrillary degeneration. Methods for screening for tau aggregation inhibitors have been developed and potential small molecule candidate compounds have been identified (Chirita *et al.*, 2004; Pickhardt *et al.*, 2005).

At present, however, the exact properties of the presumed neurotoxic form of abnormal tau protein and the precise role of hyperphosphorylation and aggregation in the pathological processes are not clear. Recent findings in mice transgenic for wild-type or mutant human tau indicate that tau-related neurodegeneration can occur independently of NFT formation and that NFTs do not invariably cause neuronal loss (Andorfer *et al.*, 2005; Santacruz *et al.*, 2005). It has also been proposed that aggregation of hyperphosphorylated tau into PHFs may represent a protective mechanism to sequester toxic forms of abnormal tau protein (Lee *et al.*, 2005b). A similar protective function of protein aggregation has been shown for huntingtin (Arrasate *et al.*, 2004).

Other approaches

Markers of neuroinflammation including activated microglia and astrocytes, complement components and inflammatory cytokines are typically observed in association with Alzheimer's disease neuropathology (for review, see McGeer and McGeer, 2003; Tuppo and Arias, 2005). Observational retrospective and prospective studies indicated that the long-term use of NSAIDs may have a preventive effect against the development of Alzheimer's disease (reviewed in Szekely *et al.*, 2004) suggesting that neuroinflammation may contribute to the neurodegeneration.

The selective cyclooxygenase (COX)-2 inhibitor rofecoxib and the non-selective NSAID, naproxen, were also tested in a clinical randomized control trial for the treatment of mild to moderate Alzheimer's disease, but neither drug was able to slow the rate of cognitive decline as compared with the placebo control group (Aisen *et al.*, 2003). Some NSAIDs including ibuprofen can modify γ -secretase activity in such a way that, specifically, the production of A β 42 peptides is decreased (see above and Weggen *et al.*, 2001). In APP-transgenic mice, ibuprofen reduced amyloid load and microglial activation (Lim *et al.*, 2000) suggesting an effect at an early stage of plaque pathology.

Cholesterol metabolism appears to play an important role in the biology of APP and possibly also in the pathological processes leading to Alzheimer's disease. APP processing and A β production are sensitive to cholesterol levels (Simons *et al.*, 1998). The activities of both, β - and γ -secretase, were shown to be inhibited by lowering cholesterol in cultured neurons (Cordy *et al.*, 2003; Wahrle *et al.*, 2002). Treatment with cholesterol lowering drugs reduced A β levels *in vivo* in cerebrospinal fluid of guinea pigs (Fassbender *et al.*, 2001) and alleviated A β pathology in transgenic mice (Refolo *et al.*, 2001). In humans, lovastatin was reported to reduce serum A β concentration in a dose-dependent manner (Friedhoff *et al.*, 2001; cited in Wolozin, 2004). Retrospective epidemiological studies indicated a reduced risk of developing dementia in patients taking statins (Jick *et al.*, 2000; Wolozin *et al.*, 2000). In contrast, three prospective studies failed to show a protective effect of statins with regard to cognitive function (Shepherd *et al.*, 2002; Heart Protection Study Collaborative Group, 2002; Li *et al.*, 2004a). Interestingly, elevated plasma cholesterol levels were reported in individuals carrying the apolipoprotein epsilon 4 allele (*APOE4*; Sing and Davignon, 1985; Ehnholm *et al.*, 1986), which is the major genetic risk factor for Alzheimer's disease (Corder *et al.*, 1993; Poirier *et al.*, 1993). At present, the exact mechanism by which *APOE4* affects the pathophysiology of Alzheimer's disease is not clear. A recent meta-analysis did not reveal Alzheimer's disease associated polymorphisms in cholesterol-related genes other than *APOE* and it was therefore concluded that the link between Alzheimer's disease and *APOE4* was probably not directly related to cholesterol (Wolozin *et al.*, 2006).

Summary and conclusions

Medications for the treatment of Alzheimer's disease that are available today include cholinesterase inhibitors and the NMDA-receptor antagonist, memantine. These drugs are safe and in several large and independent studies, they were reported to produce moderate symptomatic benefits. At present, however, there is no treatment available that can stop the progressive deterioration of cognitive functions in the Alzheimer's disease patients. The development of novel drugs with strong disease-modifying properties therefore represents one of the biggest unmet medical needs today.

The pathophysiology of Alzheimer's disease and the search for novel therapeutic strategies have been a major focus of academic and industry research for several years. The predominant hypothesis to explain the pathogenesis is the amyloid cascade hypothesis, and consequently, several of the novel and promising therapeutic strategies are specifically addressing the amyloid pathology.

Whether anti A β -immunotherapy, small molecule secretase inhibitors, other A β lowering approaches or aggregation inhibitors will turn out to be safe and will be able to stop or slow down disease progression remains to be seen.

Conflict of interest

The authors would like to mention that M.S. is an employee of Novartis in Basle, Switzerland and H.-W.K. was an employee of NADAG and Sirenade Pharmaceuticals (the latter resulted from the merger of NADAG and Siren AG) and was involved in research activities aiming for the discovery of kinase inhibitors as potential medications for Alzheimer's disease.

Acknowledgements

H.-W.K. is supported by the grant HBPP-NGFN2 (01 GR 0447) funded by the German Federal Ministry of Education and Science (BMBF). J.W. is supported by the BMBF funded grants Competence Net Dementias (01 GI 0420) and HBPP-NGFN2 (01 GR 0447). Funding to pay the Open Access publication charges for this article was provided by the BMBF funded grant Competence Net Dementias (01 GI 0420).

References

- Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. *J Immunol* 2005; 174: 1580–6.
- Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. *JAMA* 2003; 289: 2819–26.
- Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. *Proc Natl Acad Sci USA* 1994; 91: 5562–6.
- Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. *Allgemeine Zeitschrift für Psychiatrie und Psychisch-gerichtliche Medizin* 1907; 64: 146–8.
- Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. *Zeitschrift für die Gesamte Neurologie und Psychiatrie* 1911; 4: 356–85.
- Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. *J Neurosci* 2005; 25: 5446–54.
- Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia (Cochrane Review). *Cochrane Database Syst Rev* 2005; 2.
- Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. *Nature* 2004; 431: 805–10.
- Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992; 42: 631–9.
- Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. *J Biol Chem* 1998; 273: 12817–26.
- Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. *Nat Med* 2001; 7: 369–72.
- Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. *J Neurosci* 2002; 22: 7873–8.
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nat Med* 2000; 6: 916–9.
- Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. *Proc Natl Acad Sci USA* 2003; 100: 2023–8.
- Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science* 1982; 217: 408–14.
- Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. *Neurology* 2005; 64: 94–101.
- Bick KL. The early story of Alzheimer disease. In: Terry RD, Katzmann R, Bick KL, editors. *Alzheimer disease*. New York: Raven Press; 1994.
- Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron* 2005; 45: 675–88.
- Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev* 2003; CD001190.
- Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst Rev* 2000; CD001191.
- Bleich S, Romer K, Wiltfang J, Kornhuber J. Glutamate and the glutamate receptor system: a target for drug action. *Int J Geriatr Psychiatry* 2003; 18: S33–40.
- Boggs J. Toxicity issues halt PBT1 program in Alzheimer's; Prana's stock falls. *Bioworld online* April 13th, 2005.
- Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. *Neuron* 1996; 17: 1005–13.
- Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. *Brain* 1976; 99: 459–96.
- Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol (Berl)* 1991; 82: 239–59.
- Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 1995; 16: 271–8, discussion 278–84.
- Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. *Neuron* 1993; 10: 1089–99.
- Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. *J Clin Invest* 2005; 115: 428–33.
- Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* 2000; 33: 95–130.
- Bullock R. Future directions in the treatment of Alzheimer's disease. *Expert Opin Investig Drugs* 2004; 13: 303–14.
- Burns A, Byrne EJ, Maurer K. Alzheimer's disease. *Lancet* 2002; 360: 163–5.
- Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. *Am J Pathol* 2004; 165: 987–95.
- Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. *J Neurosci* 2005; 25: 9096–101.
- Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. *Neuron* 2006; 49: 671–82.
- Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. *Nature* 1998; 395: 755–6.
- Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. *Proc Natl Acad Sci USA* 1999; 96: 14088–93.
- Chartier-Harlin MC, Crawford F, Houlihan H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. *Nature* 1991; 353: 844–6.

- Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron* 2001; 30: 665–76.
- Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. *Biochemistry* 2004; 43: 2879–87.
- Citron M. Strategies for disease modification in Alzheimer's disease. *Nat Rev Neurosci* 2004; 5: 677–85.
- Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. *Nature* 1992; 360: 672–4.
- Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. *Nat Med* 1997; 3: 67–72.
- Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. *Ann Intern Med* 2003; 138: 400–10.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993; 261: 921–3.
- Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc Natl Acad Sci USA* 2003; 100: 11735–40.
- Corey-Bloom J, Anand R, Veach J. For the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. *Int J Geriatr Psychopharmacol* 1998; 1: 55–65.
- Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. *Int Immunol* 2003; 15: 505–14.
- Cruts M, Rademakers R. Alzheimer Disease & Frontotemporal Dementia Mutation Database. Available at: <http://www.molgen.ua.ac.be/ADMutations/>. Accessed 2006.
- Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. *Neuron* 2003; 40: 471–83.
- Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. *Am J Geriatr Psychiatry* 1998; 6: S64–78.
- Cummings JL. Alzheimer's disease. *N Engl J Med* 2004; 351: 56–67.
- Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma^{-/-} knock-out mice. *J Neurosci* 2003; 23: 8532–8.
- Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet* 1976; 2: 1403.
- Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. *JAMA* 1999; 281: 1401–6.
- De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. *Neuron* 2003; 38: 9–12.
- De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. *Nature* 1998; 391: 387–90.
- DeKosky ST, Ikonovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. *Ann Neurol* 2002; 51: 145–55.
- Delacourte A, Defossez A. Alzheimer's disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. *J Neurol Sci* 1986; 76: 173–86.
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 2001; 98: 8850–5.
- DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. *Science* 2002; 295: 2264–7.
- Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. *Trends Genet* 2005; 21: 664–72.
- Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nat Neurosci* 2002; 5: 452–7.
- Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001; 56: 1154–66.
- Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow EM, Biernat J, Goris J, et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. *EMBO J* 1992; 11: 2131–8.
- Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. *Brain* 2003; 126: 1935–9.
- Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. *Nature* 1996; 383: 710–3.
- Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. *J Lipid Res* 1986; 27: 227–35.
- Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. *Science* 1990; 248: 1122–4.
- Fassbender K, Simons M, Bergmann C, Strock M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. *Proc Natl Acad Sci USA* 2001; 98: 5856–61.
- Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. *Brain Pathol* 2004; 14: 11–20.
- Fisher A. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. *Jpn J Pharmacol* 2000; 84: 101–12.
- Flament S, Delacourte A, Hemon B, Defossez A. Characterization of two pathological tau protein, variants in Alzheimer brain cortices. *J Neurol Sci* 1989; 92: 133–41.
- Forsyth E, Ritzline PD. An overview of the etiology, diagnosis, and treatment of Alzheimer disease. *Phys Ther* 1998; 78: 1325–31.
- Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. *Neurology* 2005; 64: 1563–72.
- Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. *Proc Natl Acad Sci USA* 2000; 97: 11455–9.
- Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. *Int J Neuropsychopharmacol* 2001; 4: 127–30.
- Frolich L. The cholinergic pathology in Alzheimer's disease—discrepancies between clinical experience and pathophysiological findings. *J Neural Transm* 2002; 109: 1003–13.
- Fukutani Y, Kobayashi K, Nakamura I, Watanabe K, Isaki K, Cairns NJ. Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. *Neurosci Lett* 1995; 200: 57–60.
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. *Nature* 1995; 373: 523–7.
- Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, et al. Alzheimer's Abeta vaccination of rhesus monkeys (*Macaca mulatta*). *Mech Ageing Dev* 2004; 125: 149–51.

- Giasson BI, Sampathu DM, Wilson CA, Vogelsberg-Ragaglia V, Mushynski WE, Lee VM. The environmental toxin arsenite induces tau hyperphosphorylation. *Biochemistry* 2002; 41: 15376–87.
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* 2005; 64: 1553–62.
- Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 1984; 120: 885–90.
- Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 1991; 349: 704–6.
- Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. *Proc Natl Acad Sci USA* 1988; 85: 4051–5.
- Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron* 1992; 8: 159–68.
- Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. *FEBS Lett* 1997; 409: 57–62.
- Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 1997; 41: 17–24.
- Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. *J Neurochem* 1995; 65: 732–8.
- Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. *J Biol Chem* 2000; 275: 5535–44.
- Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. *J Biol Chem* 2001; 276: 529–34.
- Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J Biol Chem* 1986a; 261: 6084–9.
- Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci USA* 1986b; 83: 4913–7.
- Gustke N, Steiner B, Mandelkow EM, Biernat J, Meyer HE, Goedert M, et al. The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. *FEBS Lett* 1992; 307: 199–205.
- Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. *Nature* 1992; 359: 322–5.
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 2002; 297: 353–6.
- Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. *J Neurosci* 1999; 19: 8876–84.
- Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. *J Neurosci* 2005; 25: 6213–20.
- Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, Ihara Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. *J Biol Chem* 1992; 267: 17047–54.
- Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. *FEBS Lett* 1996; 384: 25–30.
- Heart Protection Study Collaborative Group (2002), MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7–22.
- Ho DT, Shayan H, Murphy TH. Okadaic acid induces hyperphosphorylation of tau independently of mitogen-activated protein kinase activation. *J Neurochem* 1997; 68: 106–11.
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science* 1996; 274: 99–102.
- Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. *J Biol Chem* 1993; 268: 22959–62.
- Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. *Mol Cell Neurosci* 1999; 14: 419–27.
- Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 1998; 393: 702–5.
- Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int* 2004; 45: 583–95.
- Iqbal K, Grundke-Iqbal I. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies. *Curr Drug Targets* 2004; 5: 495–502.
- Iqbal K, Zaidi T, Bancher C, Grundke-Iqbal I. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. *FEBS Lett* 1994; 349: 104–8.
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature* 2000; 408: 979–82.
- Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. *Mol Psychiatry* 2004; 9: 984–97–979.
- Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet* 2000; 356: 1627–31.
- Johnson GVV, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. *Alzheimer's Dis Rev* 1998; 3: 125–141.
- Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *BMJ* 2005; 331: 321–7.
- Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 1987; 325: 733–6.
- Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. *J Biol Chem* 2006; 281: 1205–14.
- Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. *Nature* 1963; 197: 192–3.
- Kins S, Cramer A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. *J Biol Chem* 2001; 276: 38193–200.
- Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. *Nat Med* 2005; 11: 556–61.
- Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. *Neurosci Lett* 1995; 195: 137–9.
- Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. *Biol Psychiatry* 1997; 41: 135–44.
- Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. *Eur J Pharmacol* 1989; 166: 589–90.
- Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci USA* 1986; 83: 4044–8.

- Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. *J Neurosci* 2002; 22: 6331–5.
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci USA* 1998; 95: 6448–53.
- Latimer DA, Gallo JM, Lovestone S, Miller CC, Reynolds CH, Marquardt B, et al. Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. *FEBS Lett* 1995; 365: 42–6.
- Lau LF, Schachter JB, Seymour PA, Sanner MA. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. *Curr Top Med Chem* 2002; 2: 395–415.
- Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. *Proc Natl Acad Sci USA* 2006; 103: 9673–8.
- Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. *FEBS Lett* 2005a; 579: 2564–8.
- Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? *Trends Mol Med* 2005b; 11: 164–9.
- Lee VM, Balin BJ, Otvos L Jr. Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. *Science* 1991; 251: 675–8.
- Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. *Annu Rev Neurosci* 2001; 24: 1121–59.
- Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. *Neurobiol Dis* 2003; 14: 10–8.
- Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a non-human primate, the Caribbean vervet. *Am J Pathol* 2004; 165: 283–97.
- Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA. Abeta1–15 is less immunogenic than Abeta1–40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. *Vaccine* 2003; 21: 2197–206.
- Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 1995; 269: 973–7.
- Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. *Nat Genet* 2000; 25: 402–5.
- Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. *Neurology* 2004a; 63: 1624–8.
- Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. *FEBS Lett* 2004b; 566: 261–9.
- Li Q, Cao C, Chackerian B, Schiller J, Gordon M, Ugen KE, et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. *BMC Neurosci* 2004c; 5: 21.
- Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. *J Neurosci* 2000; 20: 5709–14.
- Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. *J Biol Chem* 1984; 259: 5301–5.
- Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. *Nature* 2003; 424: 556–61.
- Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. *J Neurosci* 2003; 23: 10879–83.
- Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. *Proc Natl Acad Sci USA* 1994; 91: 12243–7.
- Loy C, Schneider L. Galantamine for Alzheimer's disease. *Cochrane Database Syst Rev* 2004, CD001747.
- Lu KP. Pinning down cell signaling, cancer and Alzheimer's disease. *Trends Biochem Sci* 2004; 29: 200–9.
- Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature* 1999; 399: 784–8.
- Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO J* 2001; 20: 27–39.
- Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. *Nat Neurosci* 2001; 4: 231–2.
- Maier M, Seabrook TJ, Lemere CA. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). *Vaccine* 2005; 23: 5149–59.
- Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. *Trends Cell Biol* 1998; 8: 425–7.
- Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. *Neurology* 2005; 64: 129–31.
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA* 1985; 82: 4245–9.
- Maurer K, Volk S, Gerbaldo H, Auguste D and Alzheimer's disease. *Lancet* 1997; 349: 1546–9.
- McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; 27: 741–9.
- McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. *Trends Genet* 2006; 22: 281–9.
- McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. *Nat Med* 2002; 8: 1263–9.
- Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. *Neurobiol Dis* 2002a; 9: 88–93.
- Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. *Neuroscience* 2002b; 110: 627–39.
- Monsonog A, Zota V, Karni A, Krieger JL, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. *J Clin Invest* 2003; 112: 415–22.
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 2000; 408: 982–5.
- Morrison JH, Hof PR. Life and death of neurons in the aging brain. *Science* 1997; 278: 412–9.
- Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. *Science* 1991; 254: 97–9.
- Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat Med* 2003; 9: 448–52.
- Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. *Neuron* 2003; 38: 555–65.

- Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc Natl Acad Sci USA* 2005; 102: 6990–5.
- Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. *N Engl J Med* 2003; 348: 1356–64.
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron* 2003; 39: 409–21.
- Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. *Neuron* 2004; 43: 321–32.
- Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, et al. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. *J Biol Chem* 1990; 265: 4492–7.
- Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. *Neurology* 2003; 61: 46–54.
- Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. *Brain Res Mol Brain Res* 2002; 109: 45–55.
- Perry EK. The cholinergic hypothesis—ten years on. *Br Med Bull* 1986; 42: 63–9.
- Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. *Lancet* 1977; 1: 189.
- Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. *Neuroreport* 1999; 10: 2411–5.
- Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. *Science* 2002; 298: 1379.
- Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. *J Biol Chem* 2005; 280: 3628–35.
- Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. *J Neurosci* 1993; 13: 1676–87.
- Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S, Apolipoprotein E polymorphism and Alzheimer's disease. *Lancet* 1993; 342: 697–9.
- Prana-Biotechnology. Prana Biotechnology cancels plans for plaque clinical study. Press release 11 April 2005. http://www.pranabio.com/company_profile/press_releases_item.asp?id=90, 2005.
- Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. *J Neurosci* 2005; 25: 629–36.
- Ramakrishnan P, Dickson DW, Davies P. Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. *Neurobiol Dis* 2003; 14: 251–64.
- Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. *Neurobiol Dis* 2001; 8: 890–9.
- Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. *Am J Geriatr Psychiatry* 2004; 12: 358–69.
- Roberts SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. *Hum Mol Genet* 2001; 10: 1317–24.
- Roder HM, Ingram VM. Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. *J Neurosci* 1991; 11: 3325–43.
- Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. *Neurology* 1998; 50: 136–45.
- Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ* 1999; 318: 633–8.
- Santacruz K, Lewis J, Spire T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. *Science* 2005; 309: 476–81.
- Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. *Lancet Neurol* 2003; 2: 539–47.
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 1999; 400: 173–7.
- Selkoe DJ. The molecular pathology of Alzheimer's disease. *Neuron* 1991; 6: 487–98.
- Sergeant N, Bussiere T, Vermersch P, Lejeune JP, Delacourte A. Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. *Neuroreport* 1995; 6: 2217–20.
- Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. *Nature* 1992; 359: 325–7.
- Shahani N, Brandt R. Functions and malfunctions of the tau proteins. *Cell Mol Life Sci* 2002; 59: 1668–80.
- Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360: 1623–30.
- Sherrington R, Rogae EI, Liang Y, Rogae EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 1995; 375: 754–60.
- Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. *Science* 1992; 258: 126–9.
- Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. *Clin Neuropharmacol* 2005; 28: 126–32.
- Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci USA* 1998; 95: 6460–4.
- Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. *Am J Hum Genet* 1985; 37: 268–85.
- Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. *Nature* 1999; 402: 537–40.
- Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. *Science* 1990; 248: 492–5.
- Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. *Vaccine* 2005; 23: 2327–30.
- Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. *Proc Natl Acad Sci USA* 1997; 94: 4109–12.
- Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope. *Pharmacol Res* 2005; 51: 1–17.
- Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc Natl Acad Sci USA* 1998; 95: 7737–41.
- Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, et al. Glycogen synthase kinase-3beta phosphorylates

- protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. *J Biol Chem* 2000; 275: 41340–9.
- St George Hyslop P, Petit A. Molecular biology and genetics of Alzheimer's disease. *C R Biol* 2004; 328: 119–30.
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proc Natl Acad Sci USA* 1997; 94: 13287–92.
- Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. *Science* 1994; 264: 1336–40.
- Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. *Neuroepidemiology* 2004; 23: 159–69.
- Tamaoka A, Odaka A, Ishibashi Y, Usami M, Sahara N, Suzuki N, et al. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1–42/43 and a beta 1–40) in familial Alzheimer's disease brain. *J Biol Chem* 1994; 269: 32721–4.
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding CA. 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. *Neurology* 2000; 54: 2269–76.
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA* 2004; 291: 317–24.
- Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. *J Neuropathol Exp Neurol* 1963; 22: 629–42.
- Tolnay M, Probst A. Review: tau protein pathology in Alzheimer's disease and related disorders. *Neuropathol Appl Neurobiol* 1999; 25: 171–87.
- Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. *Int J Biochem Cell Biol* 2005; 37: 289–305.
- Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 1999; 286: 735–41.
- Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. *Neurobiol Dis* 2002; 9: 11–23.
- Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. *Nature* 2001; 414: 212–6.
- Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. *Cell* 1989; 57: 115–26.
- Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. *Ann Neurol* 2000; 48: 567–79.
- Wenk GL, Quack G, Moebius HJ, Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. *Life Sci* 2000; 66: 1079–83.
- Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. *Int J Geriatr Psychiatry* 2004; 19: 624–33.
- Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. *Brain Res* 1986; 371: 146–51.
- Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. *J Neurosci* 2003; 23: 3745–51.
- Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates A beta plaque removal following intracranial anti-A beta antibody administration. *Neurobiol Dis* 2004a; 15: 11–20.
- Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. *J Neurosci* 2004b; 24: 6144–51.
- Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against A beta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. *J Neuroinflammation* 2004c; 1: 24.
- Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. *J Neurol Sci* 1982; 56: 343–56.
- Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology* 2001; 57: 489–95.
- Wischnik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. *Proc Natl Acad Sci USA* 1988; 85: 4506–10.
- Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, et al. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. *J Biol Chem* 1995; 270: 4916–22.
- Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature* 1999; 398: 513–7.
- Wolozin B. Cholesterol and the biology of Alzheimer's disease. *Neuron* 2004; 41: 7–10.
- Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol* 2000; 57: 1439–43.
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. *Acta Neurol Scand Suppl* 2006; 185: 63–70.
- Yagishita S, Itoh Y, Nan W, Amano N. Reappraisal of the fine structure of Alzheimer's neurofibrillary tangles. *Acta Neuropathol (Berl)* 1981; 54: 239–46.
- Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. *Nature* 1999; 402: 533–7.
- Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. *Mol Cell* 2000; 6: 873–83.
- Zurbriggen R, Amacker M, Kammer AR, Westerfeld N, Borghgraef P, Van Leuven F, et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. *J Mol Neurosci* 2005; 27: 157–66.